infohep news

• Coronavirus

  Will people with liver disease be prioritised for COVID-19 vaccination?

  Keith Alcorn / 19 January 2021

  People with decompensated cirrhosis should be prioritised for COVID-19 vaccination and immunosuppressive treatment after a liver transplant should not be a barrier to vaccination, an international panel of liver experts has concluded. Their review ...

• Hepatitis C elimination

  What's needed to eliminate hepatitis C in people with HIV in Scotland?

  Keith Alcorn / 18 January 2021

  To eliminate hepatitis C in people with HIV in Scotland, healthcare providers will need to reach people not on HIV treatment and step up testing for hepatitis C in people ...

• Access to medicines & diagnostics

  Public-sector hepatitis C treatment programmes expanding in lower- and middle-income countries

  Keith Alcorn / 08 January 2021

  Public-sector hepatitis C treatment programmes have cured tens of thousands of people in lower- and lower-middle-income countries with the aid of low-cost direct-acting antivirals and diagnostics, a simplified approach to treatment and large-scale ...

• Experimental treatments for NASH/NAFLD

  Semaglutide alone or in combination regimens shows promise for NASH

  Liz Highleyman / 18 December 2020

  Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ...

• Experimental treatments for NASH/NAFLD

  Lanifibranor improves NASH in 24-week trial

  Keith Alcorn / 18 December 2020

  Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ...